Use of Port-A-Cath in pediatric cancer patients: Experience from a tertiary cancer center in south India

Abstract

e20747 Background: Implanted subcutaneous (s.c.) central venous port accesses including Port-A-Cath (PAC) facilitate the administration of chemotherapy or blood products and are frequently used in children with cancer. We present our experience of PACs in paediatric cancer patients from a tertiary cancer centre in South India. Methods: A total of 20 patients with paediatric malignancies requiring PAC were included in the study. Aim was to review our experience of PAC and analyse the outcome in paediatric cancer patients in Indian setting. A record of all complications and final outcome were analysed. Results: A total of 20 PAC were placed. Disease distribution included ALL(80%), AML(5%), NHL(5%), neuroblastoma (5%) and RMS (5%). PAC has been in place for 2 to 36 months (cumulative 400 months). Portal infection (Coagulase-negative staphylococci) was observed in four patients of whom 3 patients had their PAC removed (portal occlusion also seen in one of the pt). Conclusions: Although, catheter-related infections demanded PAC removal in 15% of our patients, their benefits (excluding cost 300 $) argue for continued PAC use in the paediatric cancer population as it is safe and has many advantages compared to traditional CVCs in use. Strict indications, meticulous implantation technique, and adequate handling are, however, mandatory. No significant financial relationships to disclose.